{"id":169742,"date":"2025-08-04T08:27:16","date_gmt":"2025-08-04T12:27:16","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169742"},"modified":"2025-08-04T08:27:16","modified_gmt":"2025-08-04T12:27:16","slug":"glaxosmithkline-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-down-1-net-profit-rises-13-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-down-1-net-profit-rises-13-yoy\/","title":{"rendered":"GlaxoSmithKline Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Down 1%, Net Profit Rises 13% YoY"},"content":{"rendered":"<p>GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) is a leading pharmaceutical company focused on researching, manufacturing, and making available a broad range of medicines and vaccines that benefit people in India and globally. The company consistently delivers innovation and quality across its therapeutic portfolio.<br \/>\n(Source: Company Website)<\/p>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/b1382030-78c7-4eef-a7c3-867ae9fd65b6.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26 Earnings Summary (Apr\u2013Jun 2025)<\/a><\/p>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b9805 crore, down 1.23% year-on-year (YoY) from \u20b9815 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b9570 crore, down 5.0% YoY from \u20b9600 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9205 crore, up 12.64% from \u20b9182 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b912.10, up 12.45% from \u20b910.76 YoY.<\/li>\n<\/ul>\n<p><strong>Operational &amp; Strategic Update<\/strong><\/p>\n<ul>\n<li><strong>Revenue Performance:<\/strong> Marginal decline in revenue reflects a stable demand base, with product mix and portfolio optimization balancing out market pressures.<\/li>\n<li><strong>Expense Management:<\/strong> Robust 5% reduction in expenses demonstrates strong cost discipline, improved operational efficiencies, and strategic prioritization\u2014enabling margin expansion.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/b1382030-78c7-4eef-a7c3-867ae9fd65b6.pdf\" target=\"_blank\" rel=\"noopener\">Profitability Growth<\/a><strong>:<\/strong> Solid increase in net profit and EPS despite steady revenues underscores efficient expense control, favorable mix of high-margin products, and a focus on operational improvement.<\/li>\n<li><strong>Product Portfolio:<\/strong> GSK Pharma continues to focus on core therapy areas, strengthening both prescription brands and vaccines, leveraging trusted legacy products and introducing new launches.<\/li>\n<li><strong>Innovation &amp; Quality:<\/strong> Ongoing investment in research and global collaboration helps sustain the pipeline of innovative therapies and supports regulatory compliance.<\/li>\n<li><strong>Strategic Initiatives:<\/strong> Expanded digital outreach, improved supply chain, and focus on customer engagement have contributed positively to performance.<\/li>\n<\/ul>\n<p><strong>Corporate Developments<\/strong><\/p>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/b1382030-78c7-4eef-a7c3-867ae9fd65b6.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> demonstrates GlaxoSmithKline Pharmaceuticals\u2019 resilience, with profitable growth driven by operational efficiencies and prudent cost management\u2014even as revenue moderated. The company\u2019s focus on its core therapeutic strengths and patient-centric approach underpins its continued market leadership.<\/p>\n<p><strong>Looking Ahead<\/strong><\/p>\n<p>GlaxoSmithKline Pharmaceuticals Ltd is well-positioned to sustain profitability through new product launches, further cost optimization, and by deepening engagement in the Indian healthcare space. Continued innovation and expansion in vaccines and specialty medicines will be critical for future growth and stakeholder value creation through FY26 and beyond.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169743\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) is a leading pharmaceutical company focused on researching, manufacturing, and making available a broad range of medicines and vaccines that benefit people in India and globally. The company consistently delivers innovation and quality across its therapeutic portfolio. (Source: Company Website) Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: \u20b9805 crore, down [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169743,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169742","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLA.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169930,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","url_meta":{"origin":169742,"position":0},"title":"Alembic Pharmaceuticals Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 8, 2025","format":false,"excerpt":"Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"APLLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":169742,"position":1},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170458,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-q1-fy26-earnings-results\/","url_meta":{"origin":169742,"position":2},"title":"Aarti Pharmalabs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Pharmalabs Ltd, incorporated in 2019, is a manufacturer of pharmaceuticals and nutraceuticals. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9386 crore, down 30.45% year-on-year (YoY) from \u20b9555 crore in Q1 FY25. Total Expenses: \u20b9323 crore, down 33.26% YoY from \u20b9484 crore. Consolidated Net\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIPAHRM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169824,"url":"https:\/\/alphastreet.com\/india\/j-b-chemicals-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-up-9-net-profit-rises-14-yoy\/","url_meta":{"origin":169742,"position":3},"title":"J B Chemicals &#038; Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 9%, Net Profit Rises 14% YoY","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"J.B. Chemicals and Pharmaceuticals Limited (JBCPL), established in 1976, stands as one of India\u2019s prominent pharmaceutical firms with a strong integrated presence in both domestic and global markets. Renowned for its commitment to affordable, high-quality medicines, JBCPL continues to build trust among healthcare professionals and patients across geographies. Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":169742,"position":4},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":169742,"position":5},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169742"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169742\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169743"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}